ImClone Systems Inc (formerly IMCL)

[jbog]

Imclone Pipeline notes.....



1- Study Using IMC-A12 With or Without Cetuximab in Patients With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFr Therapy.

Colorectal Cancer 72 refractory patients Randomized between A12 versus A12/Cet


2- Study of IMC-A12, Alone or in Combination With Cetuximab, in Patients With Recurrent or MSCC of the Head and Neck

Head and Neck Cancer 90 refractory patients Randomized between A12 versus A12/Cet


3- Safety Study of IMC-1121B With or Without Dacarbazine to Treat Metastatic Malignant Melanoma

Metastatic Malignant Melanoma: 104 1st line patients Randomized between IMC1121B versus Dacarbazine/IMC-1121B


4- Study of IMC-1121B in Patients With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

Liver Cancer: 40 1st line patients receiving IMC-1121B Mono.


5- IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor

ES/PPN: 48 refractory children given IMC-A12 only.


6- Study With IMC-A12 in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer

Adenocarcinoma of the Prostate: 30 1st line patients reveiving IMC-A12 only.


7- IMC-1121B in Pts With Met.Renal Cell Carcinoma w/Disease Prog. on or Intol. to Tyrosine Kinase Inhibitor Therapy

Metastatic Renal Cell Carcinoma: 36 refractory patients receiving IMC- A12 Only


8- IMC-11F8 in Pts with treatment-naive locally-advanced or metastatic colorectal cancer.

MCRC: 40 patients are expected to be enrolled receiving Folfox/IMC-11F8.